Biological therapies for your injectable & oral nutrients

By ahhb
Tuesday, 15 December, 2015




With over 40 years of sterile manufacturing experience, Biological Therapies is a TGA-licenced facility that produces TGA registered products under the strict PIC/S Code of GMP.


We manufacture a comprehensive range of injections that include:


B Complex Injections
High Dose Thiamine (B1) Injections
Vitamin B12 Injections
Vitamin C Injections
EDTA Injections


We also manufacture a specialised range of oral liquid supplements targeting the needs and requirements of hospitals, these include:


Vitamins A, D & E Oral Liquid
Vitamins A & E Oral Liquid
Vitamin D3 Oral Liquid (1,000IU/0.2mL)
Magnesium Oral Liquid
Magnesium Complex Oral Liquid
Micro-Minerals Oral Liquid
Trace Elements Oral Liquid
Zinc Oral Liquid


Biological Therapies ONLY:

  • Manufactures products to the strict standards of European PIC/S Code of GMP.

  • Produces low allergy products with the minimal use of excipients.

  • Sources the highest grades of raw materials that are recognised and licensed by the TGA.

  • Provides the highest standards of customer service.


Bio-Logical water soluble oral liquids provides patients with:

  • High quality, low allergy, low excipient raw materials making it ideal for most patients.

  • An ability to vary the dose level when required.

  • An ideal dose form for those who have difficulty swallowing pills or capsules.

  • Enhanced absorption.


biological-therapies-logoFor further information including product, pricing and/or orders please contact our team on: 1800 063 948, (03) 9587 3948 or email info@biol.com.au. We are located in Suite 5, 20-30 Malcolm Road, Braeside, VIC 3195 Visit our website www.biologicaltherapies.com.au
Related Articles

GenesisCare expands with $35m Northern Beaches cancer centre

The relocated centre has expanded its services with a new radiation therapy offering and access...

In Conversation with Royal Women's Hospital CEO Sue Matthews

An hour after the final call for visitors to leave, Professor Sue Matthews — now CEO of...

Global prostate cancer rates predicted to double by 2040

The number of annual prostate cancer deaths worldwide is predicted to rise by 85% from 375,000 in...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd